WASHINGTON, D.C.—Sirtex Medical, an international leader in the treatment of advanced non-resectable liver tumors, has retained Ruder Finn as its communications agency of record. Ruder Finn will work closely with Sirtex to support ongoing professional and patient outreach in the U.S., and to develop specialized education and communication tools and services for medical centers using Sirtex’s SIR-Spheres.
SIR-Spheres are the only radioactive microspheres that are fully approved by the U.S. Food and Drug Administration to treat liver tumors.
“Ruder Finn’s experience in medical devices and cancer therapies will be of great value to us as we ramp up our efforts to reach and inform medical professionals, leading cancer treatment centers, and patients in the U.S.,” said Charles Rowland, president of Sirtex Medical, Inc., the US division of Australia’s Sirtex Medical. “With 25 cancer treatment centers already on board and others soon to follow, along with more than 500 SIR-Spheres treatments administered to date, we feel the timing is right to bring on a leading communications firm with the right resources to help us.”